References

  1. Schupp JC, ..., Jonigk DD,…. Alveolar Vascular Remodeling in Nonspecific Interstitial Pneumonia: Replacement of Normal Lung Capillaries with COL15A1 Positive Endothelial Cells. Am J Respir Crit Care Med. 2023;208(7):819-822.
  2. Verleden S, …, Länger FP, …, Jonigk D. From macroscopy to ultrastructure: an integrative approach to pulmonary pathology. Front Med (Lausanne). 2022;9:859337.
  3. Kamp JC, …, Länger F, …, Jonigk DD. Time-dependent molecular motifs of pulmonary fibrogenesis in COVID-19. Int J Mol Sci. 2022;23(3):1583.
  4. Ackermann M, …, Länger FP, …, Jonigk DD. The fatal trajectory of pulmonary COVID-19 is driven by lobular ischemia and fibrotic remodeling. EBioMedicine. 2022;14(9):2058.
  5. Kamp JC, …, Länger F, …, Jonigk DD. Comparative characterization of fibroblastic foci in pulmonary fibrogenesis. Cells. 2022;11(4):664.
  6. Jaeger B, …, Jonigk D, ….Wygrecka M, Klatt D, Schambach A, Kaminski N, Prasse A. Airway basal cells show a dedifferentiated KRT17highPhenotype and promote fibrosis in idiopathic pulmonary fibrosis. Nat Commun. 2022;13(1):5637.
  7. Ackermann M, …, Länger F, …, Jonigk D. The bronchial circulation in COVID-19 pneumonia. Am J Respir Crit Care Med. Am J Respir Crit Care Med. 2022;205(1):121-125.
  8. Walsh C, …, Jonigk D*, Ackermann M*, Lee PD*. Imaging intact human organs with local resolution of cellular structures using hierarchical phase-contrast tomography. Nat Methods. 2021;18(12):1532-1541. *Joint corresponding authors
  9. Schipke J, …, Jonigk D,... Lipofibroblasts in structurally normal, fibrotic and emphysematous human lungs. Am J Respir Crit Care Med. 2021;204(2):227-230.
  10. Hagner M, ….., Jonigk D, …. IL- 17A from innate and adaptive lyphmocytes contributes to inflammation and damage in cystic fibrosis lung disease. Eur Respir J. 2021;57(6):1900716.
  11. Ackermann M, ….., Länger F, …, Jonigk D. Pulmonary Vascular Endothelialitis, Thrombosis and Angiogenesis in COVID-19. N Engl J Med. 2020;383(2):120-128.
  12. Ackermann M, …, Jonigk D. Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. Eur Respir J. 2020;55(3):1900933.
  13. Jonigk D, …, Länger F. Morphological and molecular motifs of fibrosing pulmonary injury patterns. J Pathol Clin Res. 2019;5(4):256-271.
  14. Kordes A, …, Jonigk D,…. Genetically diverse Pseudomonas aeruginosa populations display similar transciptomic profiles in a cystic fibrosis explanted lung. Nat Commun. 2019;10(1):3397.
  15. Ackermann M, …, Jonigk D. Plexiform vasculopathy in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2017;196(8):e48-e51.
  16. Jonigk D, …, Länger F. Comparative Analysis of Morphological and Molecular Motifs in Bronchiolitis Obliterans and Alveolar Fibroelastosis after Lung and Stem Cell Transplantation. J Pathol Clin Res 2016;3(1): 17-28.
  17. Jonigk D, …, Länger F. Molecular Profiling in Lung Biopsies of Human Pulmonary Allografts to Predict Chronic Lung Allograft Dysfunction. Am J Pathol 2015;185(12): 3178-88.
  18. Bockmeyer CL, …, Länger F, Jonigk D. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012;31(7):764-72.
  19. Jonigk D, …, Länger F. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011;179(1):167-79. *shared first author
  20. Jonigk D,… , Länger F. Obliterative airway remodeling: molecular evidence for shared pathways in transplanted and native lungs. Am J Pathol 2011;179(1):167-79.